Response of mepolizumab to corticosteroids in extreme eosinophilic bronchial asthma
The following is the abstract of "Response to corticosteroids after mepolizumab in severe eosinophilic asthma
a randomized placebo-controlled crossover trial (MAPLE)" published in the November 2022 issue of Allergy
In people with severe eosinophilic asthma (SEA), mepolizumab inhibits IL-5 activity and reduces both the frequency of exacerbations
and the amount of oral corticosteroids (OCS) required for renewal.
Regardless of anti-IL-5 medication, some people continue to require OCS, suggesting persistent corticosteroid response mechanisms.
Therefore, in patients with SEA taking mepolizumab, evaluate the medical and anti-inflammatory effects of OCS.
After 12 weeks of mepolizumab treatment for adults with EAS, we conducted a randomized, triple-blind, placebo-controlled crossover trial with prednisolone
The researchers tested the effects of prednisolone and placebo on a variety of metrics associated with allergies, including symptom severity, first class of life
To Get Complete Knowledge About Health Then Check Link